-
MyChart
Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
-
Request an Appointment
Request an Appointment
If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment Information - Donate Today
MENU
Leukemia Clinical Trials
Phase I Agents for Hematologic Malignancies
- Ruxolitinib (2012-0697) (NCT01751425)
- AC220 + LD Ara-C (2012-1047) (NCT01892371)
- GSK525762 (2013-0527) (NCT01943851)
- MEDI4736 (2013-1041) (NCT02117219)
- FF-10501-01 (2014-0014) (NCT02193958)
- Ruxolitinib + DAC (2014-0344) (NCT02257138)
- OPN-305 (2014-0432) (NCT02363491)/ (2017-0887) (NCT03337451)
- Bosutinib + Inotuzumab (2014-0435) (NCT02311998)
- DS-3032B (2014-0565) (NCT02319369)
- ONC201 (2014-0731) (NCT02392572)
- BGB324 (2014-0756) (NCT02488408)
- SL-401(2014-0860) (NCT02270463)
- SL-401(2014-0976) (NCT02268253)
- AMG 330 (2015-0296) (NCT02520427)
- LY2510924 + Ida + Ara-C (2015-0436) (NCT02652871)
- FT-1101 (2015-0516) (NCT02543879)
- ADCT-402 (2015-0618) (NCT02588092)
- LY2606368 + Ara-C + Flu (2015-0665) (NCT02649764)
- AG-120 or AG-221 + 7+3 (2015-0767) (NCT02632708)
- BLU-285 (2015-0832) (NCT02561988)
- Venetoclax + Cobimetinib or Venetoclax + Idasanutlin (2015-0898) (NCT02670044)
- ADCT-402 (2015-0985) (NCT02669264)
- IMGN779 (2015-1024) (NCT02674763)
- AG-120 or AG-221 + AZA (2015-1056) (NCT02677922)
- FT-2102 (2016-0150) (NCT02719574)
- XmAb 14045 (2016-0165) (NCT02730312)
- ORH-2014 (2016-0291) (NCT03048344)
- CD33-CAR-T (2016-0341) (NCT03126864)
- H3B-8800 (2016-0547) (NCT02841540)
- INCB059872 (2016-0556) (NCT02712905)
- AMV564 (2016-0646) (NCT03144245)
- AGS62P1 (2016-0647) (NCT02864290)
- K0706 (2016-0648) (NCT02629692)
- Palbociclib (2016-0772) (NCT03132454)
- UCART123 in BPDCN (2016-0840) (NCT03203369)
- Venetoclax + AZA (2016-0944) (NCT02966782)
- CWP232291 + Ara-C (2016-1071) (NCT03055286)
- BAY 1251152 (2016-1114) (NCT02745743)
- DS-3201b (2016-1130) (NCT03110354)
- MGD006 (2017-0027) (NCT02152956)
- Ulocuplumab + LD Ara-C (2017-0092) (NCT02305563)
- ABBV-744 (2017-0172) (NCT03360006)
- AMG 176 (2017-0776) (NCT02675452)
- IMGN632 (2017-0855) (NCT03386513)
- S64315 (2017-0900) (NCT02979366)
- SEL24 (2016-0713) (NCT03008187)
- PCM-075 + LDAC (2017-0480) (NCT3303339)
- LGH447 (2017-0592) (NCT02078609)
Acute Lymphoblastic Leukemia (ALL)
Newly Diagnosed or Previously Treated
- Hyper-CVAD + INO (2015-0922) (NCT03488225)
- mHCVD + Inotuzumab +/-Blinatumomab (2010-0991) (NCT01371630)
- Venetoclax + Chemo (2016-0694) (NCT03319901)
- Hyper-CVAD + Nelarabine (2006-0328) (NCT00501826)
- Hyper-CVAD + Ponatinib (2011-0030) (NCT01424982)
- Blinatumomab + Ponatinib (2016-0792) (NCT03263572)
- Bosutinib + Inotuzumab (2014-0435) (NCT02311998)
- Hyper CVD + Ponatinib (2016-0402) (NCT03147612)
- EPOCH + Ofatumumab or Rituximab (2014-0123) (NCT02199184)
Minimal Residual Disease
- Blinatumomab (2014-0844) (NCT02458014)
- Inotuzumab (2015-0921) (NCT03441061)
Salvage Programs
- Hyper-CVAD + CMC-544 (2010-0991) (NCT01371630)
- KTE-C19 (2015-0416) (NCT02614066)
- Chemo + Blinatumomab (2017-0127) (NCT03518112)
- ADCT-402 (2015-0985) (NCT02669264)
- UCART19 (2016-0725) (NCT02746952)
- iC9/CAR (2016-0641) (NCT03056339)
- Inotuzumab (2015-0870) (NCT03094611)
- Venetoclax + Navitoclax + Chemo (2017-0679) (NCT03181126)
- Ruxolitinib or Dasatinib + HyperCVAD (2014-0521) ( NCT02420717)
- ADCT-301 (2015-0618) (NCT02588092)
- EPOCH + Ofatumumab (2014-0123) (NCT02199184)
- CEC + VCR + Bortezomib (2016-0211) (NCT03136146)
- Blinatumomab + Ponatinib (2016-0792) (NCT03263572)
- Bosutinib + Inotuzumab (2014-0435) (NCT02311998)
- Hyper CVD + Ponatinib (2016-0402) (NCT03147612)
- BL-8040 + Nelarabine (2016-1101) (NCT02763384)
- Hyper-CVAD + Nelarabine (2006-0328) (NCT00501826)
Phase I/II Open to ALL
- mHCVD + Inotuzumab +/- Blinatumomab (2010-0991) (NCT01371630)
- KTE-C19 (2015-0416) (NCT02614066)
- ADCT-402 (2015-0985) (NCT02669264)
- DS-3201B (2016-1130) (NCT03110354)
- FT-1101 (2015-0516) (NCT02543879)
- ONC201 (2014-0731) (NCT02392572)
Acute Myelogenous Leukemia (AML)
Newly Diagnosed
- Fludarabine + Ara-C + G-CSF + Gemtuzumab (2007-0147) (NCT00801489)
- ATRA and arsenic +/- Gemtuzumab (2010-0981) (NCT01409161)
- Nivolumab + Ida + Ara-C (2014-0907) (NCT02464657)
- Cladribine + Ida + Ara-C (2012-0648) (NCT02115295)
- FLAG-Ida + Venetoclax (2016-0979) (NCT03214562)
- BP1001 + LD Ara-C (2016-0128) (NCT02781883)
- Venetoclax/Placebo + LDAC (2017-0398) (NCT03069352)
- Pracinostat + AZA (2017-0173) (NCT03151408)
- Cladribine + LD Ara-C alternating DAC (2011-0987) (NCT01515527)
- Nivolumab + AZA (2014-0861) (NCT02397720)
- Venetoclax + Decitabine (2017-0912) (NCT03404193)
- Venetoxlax + AZA vs AZA (2016-0985) (NCT02993523)
- DAC (2012-1017) (NCT01786343)
- Inecalcitol + DAC (2016-0198) (NCT02802267)
- Venetoclax/Placebo + LDAC (2017-0398) (NCT03069352)
- AML123 (2017-0559) (NCT03190278)
- PCM-075 + LDAC (2017-0173) (NCT03151408)
- AG-120 or AG-221 + AZA (2015-1056) (NCT02677922)
- PDR001/MBG453 + Decitabine (2017-0256) (NCT03066648)
- SL401 + AZA (2017-0354) (NCT03113643)
- SGI-110 (2013-0843) (NCT02096055)
- Ulocuplumab + LD Ara-C (2017-0092) (NCT02305563)
FLT3 Mutated Only
- ASP2215 vs ASP2215 + AZA vs AZA (2016-0266) (NCT02752035)
- AC220 + AZA or LD Ara-C (2012-1047) (NCT01892371)
IDH Mutated only
- FT-2102 (2016-0150) (NCT02719574)
- AG120 (2017-0490) (NCT03471260)
- AG-120/placebo + AZA (2017-0848) (NCT03173248)
- AG-120 or AG-221 +7 + 3 (2015-0767) (NCT02632708)
- BAY 1436032 (2016-1084) (NCT03127735)
- IDH inhibitors + AZA (2015-1056) (NCT02677922)
Frontline AML Post-Hypomethylating Therapy for MDS
- Nivolumab + AZA (2014-0861) (NCT02397720)
- Venetoclax/Placebo + LDAC (2017-0398) (NCT03069352)
Secondary Leukemia
- Ruxolitinib + DAC (2014-0344) (NCT02257138)
Mixed Phenotype Acute Leukemia
- Clofarabine, Ida, Ara-C, VCR, and Corticosteroids (2013-0073) (NCT02135874)
Salvage
FLT3 Positive at relapse
- AlloSCT Initial Salvage Therapy (2014-0358) (NCT02441803)
- AC220 + LD Ara-C (2012-1047) (NCT01892371)
- Palbociclib (2016-0772) (NCT03132454)
- CD33-CAR-T (2016-0341) (NCT03126864)
- Venetoclax + Decitabine (2017-0912) (NCT03404193)
- Cladribine + Ida + Ara-C + Sorafenib (2012-0648) (NCT02115295)
- SY-1425 (2016-0460) (NCT02807558)
- AMG 330 (2015-0296) (NCT02520427)
- XmAb 14045 (2016-0165) (NCT02730312)
- FLAG-Ida + Venetoclax (2016-0979) (NCT03214562)
- Selinexor + Sorafenib (2014-0975) (NCT02530476)
- AMG673 (2017-0365) (NCT03224819)
- PDR001/MBG453 + Decitabine (2017-0256) (NCT03066648)
- Daratumumab (2016-0889) (NCT03067571)
RAS Mutated
- AlloSCT Initial Salvage Therapy (2014-0358) (NCT02441803)
- FLAG-Ida + Venetoclax (2016-0979) (NCT03214562)
- Venetoclax + Decitabine (2017-0912) (NCT03404193)
- CD33-CAR-T (2016-0341) (NCT03126864)
- SY-1425 (2016-0460) (NCT02807558)
- AMG 330 (2015-0296) (NCT02520427)
- AMG673 (2017-0365) (NCT03224819)
- PDR001/MBG453 + Decitabine (2017-0256) (NCT03066648)
- Daratumumab (2016-0889) (NCT03067571)
AML with MLL gene at 11q23 Translocations
- SY-1425 (2016-0460) (NCT02807558)
IDH Mutated
- AlloSCT Initial Salvage Therapy (2014-0358) (NCT02441803)
- FT-2102 (2016-0150) (NCT02719574)
- AG120 (2017-0490) (NCT03471260)
- Venetoclax + Decitabine (2017-0912) (NCT03404193)
- CD33-CAR-T (2016-0341) (NCT03126864)
- SY-1425 (2016-0460) (NCT02807558)
- AMG 330 (2015-0296) (NCT02520427)
- XmAb 14045 (2016-0165) (NCT02730312)
- PDR001/MBG453 + Decitabine (2017-0256) (NCT03066648)
- Daratumumab (2016-0889) (NCT03067571)
- AG-120 (2017-0531) (NCT03245424)
All others (Regardless of mutation status)
- Alvocidib (Flavopiridol)/Ara-C/Mitoxantrone (FLAM) (2015-0719) (NCT02520011)
- AlloSCT Initial Salvage Therapy (2014-0358) (NCT02441803)
- CD33-CAR-T (2016-0341) (NCT03126864)
- FLAG-Ida + Venetoclax (2016-0979) (NCT03214562)
- Cladribine + Ida + Ara-C + Sorafenib (2012-0648) (NCT02115295)
- SY-1425 (2016-0460) (NCT02807558)
- Nivolumab + 5-AZA (2014-0861) (NCT02397720)
- LY2606368 + Ara-C + Flu (2015-0665) (NCT02649764)
- Venetoclax + Decitabine (2017-0912) (NCT03404193)
- DS-3032B (2014-0565) (NCT02319369)
- AMG 330 (2015-0296) (NCT02520427)
- XmAb 14045 (2016-0165) (NCT02730312)
- AML123 (2017-0559) (NCT03190278)
- ADCT-301 (2015-0618) (NCT02588092)
- Avelumab (2016-0444) (NCT02953561)
- SGN-CD123 (2016-0454)
- OX40 (2017-0337) (NCT03390296)
- GO + Glasdegib (2017-0337) (NCT03390296)
- AMG673 (2017-0365) (NCT03224819)
- Daratumumab (2016-0889) (NCT03067571)
- IACS-010759 (2016-0250) (NCT02882321)
- SL401 + AZA (2017-0354) (NCT03113643)
- MGD006 (2017-0027) (NCT02152956)
- PDR001/MBG453 + Decitabine (2017-0256) (NCT03066648)
- SGI-110 (2016-0828) (NCT02920008)
Maintenance (Patients in CR)
- SL-401 (2014-0860) (NCT02270463)
- Lenalidomide (2014-0116) (NCT02126553)
- Nivolumab (2015-0213) (NCT02532231)
- BL-8040 + Atezolizumab (2017-0926) (NCT03154827)
- Cyclophosphamide (2016-0227) (NCT02709993)
Supportive Care for AML
- Isavuconazole (2016-0373) (NCT03019939)
- NLA101 (2017-0259) (NCT03301597)
BPDCN Treatment Priorities
- SL-401 (2013-0979) (NCT02113982)
- UCART 123 (2016-0840) (NCT03203369)
Myelodysplastic Syndrome (MDS) (Includes CMML)
Specific Situations
Hypoplastic MDS and aplastic anemia
- Horse ATG (2012-0334) (NCT01624805)
- BL-8040 (2015-0408) (NCT02462252)
Splicing Mutations
- H3B-8800 (2016-0547) (NCT02841540)
MDS/MPN
- Ruxolitinib + AZA (2012-0737) (NCT01787487)
- SL-401 (CMML) (2014-0976) (NCT02268253)
- ORH-2014 (2016-0291) (NCT03048344)
FLT3 Positive
- AC220 + LD Ara-C (2012-1047) (NCT01892371)
RAS Mutated
- MEK162 (2013-0116) (NCT02089230)
IDH 1 Mutations
- FT-2102 (2016-0150) (NCT02719574)
- AG221 (2016-0981) (NCT03383575)
Low Risk/IPSS Int-1
- ASTX727-02 (2017-0886) (NCT03306264)
- OPN-305 (2014-0432)/(2017-0887) (NCT02363491)
- DAC vs AZA (2014-0112) (NCT02269280)
- Roxadustat (FG-4592)/Placebo (2017-0042) (NCT03263091)
IPSS int-2 or high
- Venetoclax + AZA vs AZA Alone (2016-0757) (NCT02942290)
- ASTX727-02 (2017-0886) (NCT03306264)
- Nivolumab + Ipilimumab + Aza (2014-0930) (NCT02530463)
- SGI-110 (2013-0901) (NCT02131597)
- Pembrolizumab + AZA (2016-0343) (NCT03094637)
- CB-839 + AZA (2016-0636) (NCT03047993)
- Oral Rigosertib + AZA (2013-0030) (NCT01926587)
- Cladribine + LD Ara-C alt DAC (2011-0987) (NCT01515527)
- Cladribine + Ida + Ara-C + Sorafenib (2012-0648) (NCT02115295)
Post Hypomethylating Agents
- OPN-305 (2014-0432)/ (2017-0887) (NCT02363491)
- Nivolumab + Ipilimumab + Aza (2014-0930) (NCT02530463)
- SGI-110 (2016-0587) (NCT02907359)
- Pembrolizumab + AZA (2016-0343) (NCT03094637)
- Venetoclax + AZA (2016-0944) (NCT02966782)
- Omacetaxine (2013-0870) (NCT02159872)
- AMV564-201 (2018-0009) (NCT03516591)
- Rigosertib (2015-0360) (NCT02562443)
- CB-839 + AZA (2016-0636) (NCT03047993)
- Oral Rigosertib + AZA (2013-0030) (NCT01926587)
- FF-10501-01 (2014-0014) (NCT02193958)
- Cladribine + Ida + Ara-C + Sorafenib (2012-0648) (NCT02115295)
- MEDI4736 (2013-1041) (NCT02117219)
Chronic Lymphocytic Leukemia (CLL)
CLL Immunotherapy
Untreated - early stage
- Ruxolitinib (2015-0570) (NCT03041636)
- Ibrutinib (2017-0039) (NCT03207555)
Untreated - all stages
- FCIG (2015-0281) (NCT02629809)
- Venetoclax + Ibrutinib (2015-0860) (NCT02756897)
- CC-122 (2015-0193) (NCT02406742)
- Atezolizumab (2015-1097) (NCT02846623)
Consolidation and Minimal Residual Disease (MRD)
- ABT-199 + Ibrutinib (2016-0785) (NCT03128879)
Prior Therapy
- UC-961 + Ibrutinib (2017-0889) (NCT03088878)
- CC-122 (2015-0193) (NCT02406742)
- JCAR017 (2017-0751) (NCT03331198)
- XmAb®13676 (2016-0991) (NCT02924402)
- SNS-062 – BTK-Inhibitor (2017-0158) (NCT03037645)
- Lenalidomide + Obinutuzumab (2014-0115) (NCT02225275)
- Nivolumab + Ibrutinib (2014-0931) (NCT02420912)
- Venetoclax + Ibrutinib (2015-0860) (NCT02756897)
- iC9/CAR (2016-0641) (NCT03056339)
Richter’s Transformation
- Nivolumab + Ibrutinib (2014-0931) (NCT02420912)
- Blinatumomab (2016-0765) (NCT03121534)
- EPOCH-R + VEN (2016-0900) (NCT03054896)
Other Studies
- PCI-32765 in Hairy Cell Leukemia (2013-0299) (NCT01841723)
- 2CDA + Rituximab in Hairy Cell Leukemia (2004-0223) (NCT00412594)
Chronic Myelogenous Leukemia (CML)
Chronic phase
- Dasatinib (2015-1040) (NCT02689440) HOLD
- K0706 (2016-0648) (NCT02629692)
- Ponatinib (2015-0212) (NCT02467270)
- Axitinib + Bosutinib (2015-0787) (NCT02782403)
Accelerated Phase
- BP1001 (2016-0644) (NCT02923986)
- K0706 (2016-0648) (NCT02629692)
- Axitinib + Bosutinib (2015-0787) (NCT02782403)
Blastic Phase
- Axitinib + Bosutinib (2015-0787) (NCT02782403)
- BP1001 (2016-0644) (NCT02923986)
- Bosutinib + Inotuzumab (2014-0435) (NCT02311998)
- K0706 (2016-0648) (NCT02629692)
- DS-3032B (2014-0565) (NCT02319369)
Imatinib failures with T315l mutations (any stage)
- K0706 (2016-0648) (NCT02629692)
- Ponatinib (2015-0212) (NCT02467270)
- Axitinib + Bosutinib (2015-0787) (NCT02782403)
- Oral ABL001 (2014-1019) (NCT02081378)
Minimal Residual Disease
- Ruxolitinib (2012-0697) (NCT01751425)
Myeloproliferative Diseases
- Ruxolitinib + Thalidomide (2017-0512) (NCT03069326)
- Pacritinib (2017-0320) (NCT03165734)
- Navitoclax (2017-0495) (NCT03222609)
- Ruxolitinib + PU-H71 (2017-0750) (NCT03373877)
- INCB050465 + Ruxolitinib (2016-0233) (NCT02718300)
- Sotatercept (ACE-011) (2012-0534) (NCT01712308)
- LCL-161 (2013-0612) (NCT02098161)
- SL-401 (2014-0976) (NCT02268253)
- Ruxolitinib + AZA (2012-0737) (NCT01787487)
- Luspatercept (ACE-536) (2017-0504) (NCT03194542)
- INCB054828 (2016-0635) (NCT03011372)
- BLU-285 (2015-0832) (NCT02561988)
- Rigosertib (2014-0546) (NCT02730884)
- Ruxolitinib vs Anagrelide (2017-0111) (NCT03123588)
Hemophagocytic Lymphohistiocytosis
- Alemtuzumab + Etoposide & Dexamethasone (2014-0989)